Literature DB >> 1900671

Postprandial decrease in HDL cholesterol and HDL apo A-I in normal subjects in relation to triglyceride metabolism.

T W De Bruin1, C B Brouwer, J A Gimpel, D W Erkelens.   

Abstract

The postprandial lipoprotein metabolism is important since it determines the circulation of potentially atherogenic particles and influences the metabolism of high-density lipoproteins (HDL) in a complex manner that is at present not completely understood. Therefore, the short-term (24-h) changes in postprandial lipoprotein metabolism, including retinyl palmitate (RP), apolipoprotein A-I (apo A-I), and apolipoprotein B, were studied in relation to postheparin lipolytic activities in six healthy normolipidemic men after an oral RP fat tolerance test. The fat load (98 g) was cleared in 7 h, because the triglyceride (TG) concentrations had returned to initial values (0.72 +/- 0.31 mmol/l) at that time. RP showed a peak in plasma at 4 and 5 h but remained present in chylomicron (remnants) in low concentrations after 8 and 24 h. After the fat load, HDL cholesterol and HDL-associated apo A-I showed a significant decrease in concentration of 35 and 29%, respectively. The decrease coincided with the increase in chylomicron remnants and the transient appearance of TG-enriched HDL. Hepatic lipase was correlated to both the initial HDL cholesterol concentration as well as the peak concentration of TG in chylomicron remnants, suggesting that it could be one of the regulating common physiological pathways in postprandial HDL and TG metabolism. In the subjects studied, the atherogenic potential of plasma increased in response to an oral fat load, characterized by a decrease in HDL cholesterol and HDL-associated apo A-I.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900671     DOI: 10.1152/ajpendo.1991.260.3.E492

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Marked Influence of Adiposity on Laboratory Biomarkers in a Healthy Cohort of Children and Adolescents.

Authors:  Victoria Higgins; Arghavan Omidi; Houman Tahmasebi; Shervin Asgari; Kian Gordanifar; Michelle Nieuwesteeg; Khosrow Adeli
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

2.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Authors:  M Castro Cabezas; T W de Bruin; H W de Valk; C C Shoulders; H Jansen; D Willem Erkelens
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

3.  High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene.

Authors:  K J Lackner; H Dieplinger; G Nowicka; G Schmitz
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

4.  Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomicron-like lipid emulsions in rats and man.

Authors:  T G Redgrave; H L Ly; E C Quintao; C F Ramberg; R C Boston
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

5.  Prior exercise and postprandial incretin responses in lean and obese individuals.

Authors:  Timothy D Heden; Ying Liu; Monica L Kearney; Youngmin Park; Kevin C Dellsperger; Tom R Thomas; Jill A Kanaley
Journal:  Med Sci Sports Exerc       Date:  2013-10       Impact factor: 5.411

6.  Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women.

Authors:  U Julius; H Fritsch; W Fritsch; E Rehak; K Fücker; W Leonhardt; M Hanefeld
Journal:  Clin Investig       Date:  1994-07

7.  Oral fat load effects on inflammation and endothelial stress markers in healthy subjects.

Authors:  Giuseppe Derosa; Ilaria Ferrari; Angela D'Angelo; Sibilla A T Salvadeo; Elena Fogari; Alessia Gravina; Roberto Mereu; Ilaria Palumbo; Pamela Maffioli; Sabrina Randazzo; Arrigo F G Cicero
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

8.  Moderate sodium restriction enhances the pressor response to hyperlipidemia in obese, hypertensive patients.

Authors:  H F Lopes; M P Stojiljkovic; D Zhang; T L Goodfriend; B M Egan
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 May-Jun       Impact factor: 3.738

9.  Low-Sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans.

Authors:  Y Al-Solaiman; A Jesri; Y Zhao; J D Morrow; B M Egan
Journal:  J Hum Hypertens       Date:  2009-04-30       Impact factor: 3.012

10.  DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre.

Authors:  Y Al-Solaiman; A Jesri; W K Mountford; D T Lackland; Y Zhao; B M Egan
Journal:  J Hum Hypertens       Date:  2009-07-23       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.